[
  {
    "ts": "2025-12-07T08:10:32+00:00",
    "headline": "Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates",
    "summary": "Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...",
    "url": "https://finance.yahoo.com/news/why-narrative-around-gilead-sciences-081032449.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "04d6faf6-dc17-37c6-a9a0-a19e8ba301f9",
      "content": {
        "id": "04d6faf6-dc17-37c6-a9a0-a19e8ba301f9",
        "contentType": "STORY",
        "title": "Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates",
        "description": "",
        "summary": "Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...",
        "pubDate": "2025-12-07T08:10:32Z",
        "displayTime": "2025-12-07T08:10:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-gilead-sciences-081032449.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-gilead-sciences-081032449.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-07T13:00:00+00:00",
    "headline": "Yescarta速 Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025",
    "summary": "SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta速 (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).",
    "url": "https://finance.yahoo.com/news/yescarta-delivers-consistent-safety-efficacy-130000955.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3f07b0f8-5d31-3ce5-97ac-ec0cdcbca03a",
      "content": {
        "id": "3f07b0f8-5d31-3ce5-97ac-ec0cdcbca03a",
        "contentType": "STORY",
        "title": "Yescarta速 Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025",
        "description": "",
        "summary": "SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta速 (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).",
        "pubDate": "2025-12-07T13:00:00Z",
        "displayTime": "2025-12-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/07fe4423b9be1c8e4ac4b092128b600d",
          "originalWidth": 1595,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W_vbeMeHMgSGBRktvndONA--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/07fe4423b9be1c8e4ac4b092128b600d.cf.webp",
              "width": 1595,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zZUVVnzqgtSTjmLntSz9Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/07fe4423b9be1c8e4ac4b092128b600d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/yescarta-delivers-consistent-safety-efficacy-130000955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/yescarta-delivers-consistent-safety-efficacy-130000955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]